anaesthetic & critical care studies summaries

---

Protocol v3.1 09/11/2022
​Rotherham Principal Investigator: Professor Anil Hormis
Research team member: Dr Katie Webb

research topic:

Platform trial to evaluate therapeutic interventions for influenza

trial groups:

 Intervention: 5 or 10 days of oseltamivir +/- baloxavir on days 1+4
 Control: usual care (5 days of oseltamivir)

inclusion criteria:

• >18 years old, hospitalised with acute illness due to LRTI
• Influenza confirmed by microbiological testing

exclusion criteria:

• ​>96 hours since admission to hospital
• >48 hours since admission to critical care
• Patient has already received 2 or more doses of oseltamivir or other neuraminidase inhibitors
• Patient has already received 1 or more doses of baloxivir
• patient is already receiving, or a clinical decision has been made to commence an antiviral active against influenza other than oseltamivir or baloxivir, or both.
• The treating clinician believes that participation in the domain would not be in the best interests of the patient.
• Death is deemend to be imminent and inevitable during the next 24 hours AND one or more of the patient, substitute decision maker or attending physician are not committed to full active treatment.
• Previous participation to REMAP CAP within the last 90 days 
• Expected to be discharged from this hospital admission within the next 24 hours.
  

consent:

​Formal consent is required for REMAP CAP trial enrolment/randomisation.
​If you think your patient is in any way eligible please contact the research team who will review the full inclusion/exclusion criteria and approach for consent.